Organization (Industry)
GUERBET
ClinicalTrials.gov lists GUERBET as lead sponsor of 42 trials, counting the companies grouped under it. GUERBET itself has 1 active development program and 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers GUERBET and 1 company grouped under it: 42 lead-sponsored trials (42 its own, 0 in the grouped companies) and 4 legal-entity registrations (3 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| GUERBET IRELAND UNLIMITED COMPANY | 0 | 1 |
Disease areas (39)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Carcinoma, Hepatocellular | 9 |
| Liver Neoplasms | 9 |
| Coronary Artery Disease | 5 |
| Coronary Disease | 5 |
| Atherosclerosis | 2 |
Showing 5 of 39 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 5 |
| 2023 | 4 |
| 2022 | 5 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 5 |
Showing 10 of 22 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Gadopiclenol | Brain Neoplasms | Phase 3 | 1 |
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DOTAREM | 13 |
| Iobitridol | 3 |
| Gadobenate Dimeglumine | 2 |
| MRI | 2 |
| Gadobutrol | 2 |
Showing 5 of 23 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 90% hit target (n=10) | 0% on time (n=9) |
Journals published in (37)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Investigative radiology | 7 |
| Fertility and sterility | 6 |
| Radiology | 4 |
| European journal of radiology | 3 |
| European radiology | 3 |
Showing 5 of 37 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 73 | 14 | 2024-08-20 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 3 |
FDA recalls (2)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00. | Class II | 2019-09-13 |
| Sodium Chloride Injection USP 0.9%, packaged in 1 - 125 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1188-27. | Class III | 2019-09-13 |
Organization relationships (8)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Yale University | Co sponsors trial with | 1 |
| Bracco (Italy) | Co sponsors trial with | 1 |
| Bayer (Germany) | Co sponsors trial with | 1 |
| Samsung (South Korea) | Co sponsors trial with | 1 |
| Jae Ho Byun | Co sponsors trial with | 1 |
Showing 5 of 8 relationships.
Latest dated events (157)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-28 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-12-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 157 events.
Biomarker capability evidence (38)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| EGFR | Trial collaborator | Named in trial inclusion criteria |
| KLK3 | Trial sponsor | Named in trial inclusion criteria |
| NSF | Trial sponsor | Named in trial inclusion criteria |
| SST | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 38 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.